For example, the antagonist of EP4, RQ-00000007, is under clinical evaluation in combination with gemcitabine for prostate cancer, non-small cell lung cancer, and breast cancer (NCT02538432 www.clinicaltrials.gov). Here, PTGER4 is linked to Familial prostate cancer.